1、 1Novartis Q4 Results|February 4,2026ContentCompany overview2025 financial review2026 guidanceReferencesClick below to navigate through the documentConclusionsAppendixInvestor presentation February 4,2026Q4 2025 Results 2Novartis Q4 Results|February 4,2026ContentCompany overview2025 financial review

2、2026 guidanceReferencesClick below to navigate through the documentConclusionsAppendixDisclaimerThis presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995,that can generally be identified by words such as“plan,”“will

3、,”“continue,”“ongoing,”“growth,”“launch,”“expect,”“deliver,”“accelerate,”“guidance,”“outlook,”“priority,”“potential,”“momentum,”or similar expressions,or by express or implied discussions regarding:potential new products;potential new indications for existing products;potential product launches or p

4、otential future revenues from any such products;results of ongoing clinical trials;or potential future,pending or announced transactions,including the proposed acquisition of Avidity Biosciences,Inc.(“Avidity”)and Aviditys related spin-off or sale of Atrium Therapeutics,Inc.(“SpinCo”);the expected t

5、imetable for completing each of the proposed transactions;the composition of the assets and liabilities to be held by SpinCo and Avidity following the spin-off or sale;potential future sales or earnings;strategy,plans,expectations or intentions,including discussions regarding our continued investmen

6、t into new R&D capabilities and manufacturing;or our capital structure.Such forward-looking statements are based on the current beliefs and expectations of management regarding future events and are subject to significant known and unknown risks and uncertainties.Should one or more of these risks or